Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that Kyocera Corporation (Kyocera, TYO:6971) has signed a licence agreement to develop and commercialise Progenza for Knee Osteoarthritis (Progenza OA) in Japan.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide an update on initiation of challenge study in poultry with the recently developed bromelain-based formulation (ANR-pf).
During the quarter, Regeneus Ltd (ASX:RGS) received notification from Kyocera Corporation (TYO:6971) that its lead stem cell platform technology Progenza for the treatment of Knee Osteoarthritis (Progenza OA) had passed Kyocera's due diligence process.
While focussing financial resources on development of GaRP, Anatara has been evaluating development, in collaboration with third parties, additional dosage forms for piglets and to utilise Anatara's intellectual property in other species including in-feed formulations for piglets, formulations for aquaculture and formulations for poultry.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today provides an update on its negotiations with Kyocera Corporation (TYO:6971) for a licence agreement to develop and commercialise Progenza for Knee Osteoarthritis in Japan
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, was recently featured in the 'Under the Microscope' podcast series from Morgans.
Anatara is nearing conclusion of a process of due diligence and negotiation with many of the world's leading animal health companies. Anatara's objective being to partner with a company or companies to register Detach(R) in key overseas markets.
